Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Advanced Colorectal Cancer

Prior treatment

• Patients with uncontrollable tumor-related pain as judged by the investigator; participants requiring analgesic medication must already have a stable analgesic regimen at the time of study entry; symptomatic lesions suitable for palliative radiotherapy should be completed prior to study entry;
• Those who have received other clinical trial drug treatment within 4 weeks before preconditioning by lymphodepletion,plan to participate in other clinical trial drug treatment during the study;

Other illness

• Known mental illness, alcoholism, drug use or substance abuse;
• The investigators determine that other conditions that make the patient not suitable for enrollment

Other

• Pregnant or lactating women; or women who are pregnant, breastfeeding, or planning to become pregnant within 1 year after cell infusion;

• Voluntarily join the study, signed informed consent form， willing and able to comply with the study protocol;
• Age 18 to 70 years old;
• Advanced Colorectal Cancer that progresses after first-line chemotherapy；
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
• Expected survival time of ≥ 12 weeks;
• Good function of vital organs;
• Subjects entering this study due to disease progression must have an imaging record of disease progression before tumor sampling;
• At least one measurable target lesion that meets the definition of RECIST v1.1 after tumor sampling.